Compare ARK Genomic Revolution ETF (ARKG) vs British American Tobacco PLC (BTI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs British American Tobacco PLC — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while British American Tobacco PLC trades at $59.09 (market cap $127.15B). The key difference: British American Tobacco PLC pays a 5.56% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, British American Tobacco PLC nearer its low. Which is the better fit depends on your goals.
| ARKG | BTI | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $43.57 | $66.70 |
52-Week Low | $23.09 | $50.39 |
Market Cap | — | $127.15B |
Enterprise Value | — | $168.38B |
Dividend Yield | — | 5.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
British American Tobacco (BTI) trades at $60.02, down 1.4% on the day, with a bearish technical signal from moving averages. The company shows strong profitability with a net income margin of 30.32% and a P/E ratio of 13.02, indicating potential undervaluation. Recent earnings have mostly beaten expectations, and the firm maintains a robust dividend, with two $0.83 payouts scheduled for H2 2026. However, 2023 saw a significant net loss, and 2025 cash flow is projected negative, highlighting volatility.
BTI offers a compelling value proposition with high margins and analyst support (66.7% buy ratings), but faces headwinds from regulatory pressures, declining cigarette volumes, and restructuring costs. The stock's outlook balances income appeal against sector-specific risks, requiring careful monitoring of its transition to smoke-free products and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →
